Aarti Drugs Q1 FY27: Revenue up 19%, PAT down 7%

Key takeaways from the quarter

Aarti Drugs Limited reported a mixed set of numbers for Q1 FY27, with strong revenue growth but weaker profitability on a year-on-year basis. Consolidated revenue for the quarter ended June 30, 2026, was reported at about ₹703 crore, up from around ₹591 crore in Q1 FY26. Over the same period, consolidated profit after tax (PAT) declined to about ₹50 crore versus about ₹54 crore a year earlier. The company’s updates also included an exceptional item related to a capital work-in-progress write-off and a compliance-related development at its Saykha facility. Separately, the board approved a leadership transition, with changes scheduled from October 1, 2026.

Revenue growth: about ₹703 crore, up around 19% YoY

In its Q1 FY27 updates, Aarti Drugs reported consolidated total revenue of ₹703.59 crore, compared with ₹590.8 crore in Q1 FY26. Another figure cited for the same quarter was consolidated revenue of ₹702.78 crore versus ₹590.8 crore last year, indicating revenue was broadly around ₹703 crore. A separate market report also pegged Q1 revenue at ₹702.78 crore, compared with ₹590.51 crore in the year-ago quarter. Across these references, the reported year-on-year growth was about 19%. The company attributed the top-line rise to stable volume demand across core segments.

Profitability: consolidated PAT fell to about ₹50 crore

On profits, consolidated PAT for Q1 FY27 was reported at ₹50.13 crore, down from ₹54.0 crore in Q1 FY26, a decline of about 7% year-on-year. Another figure cited was ₹50.17 crore for the quarter, down 6.9% year-on-year from ₹53.91 crore in the corresponding quarter last year. The narrative accompanying the results pointed to margin pressures within the specialty generics segment and elevated operational and raw material cost pressures. This created a split performance where revenue growth did not translate into higher bottom-line growth.

Operating performance: EBITDA rose and margins improved

At the operating level, the quarter showed improvement in reported EBITDA and margin. A market report stated EBITDA increased 32.6% year-on-year to ₹98.20 crore from ₹74.08 crore. The EBITDA margin was reported at 13.97% for the quarter, compared with 12.55% in the year-ago period. This indicates operating profitability improved even as net profit declined, suggesting the impact of other costs and items below EBITDA.

Standalone performance: ₹627.45 crore revenue, ₹50.85 crore profit

Alongside consolidated numbers, the company disclosed standalone results for the quarter ended June 30, 2026. Standalone operations revenue was reported at ₹627.45 crore. Standalone profit for the quarter was ₹50.85 crore. These numbers were cited as part of the quarter’s data snapshot.

Exceptional item: CWIP write-off of ₹2.09 crore

The quarter also included an exceptional write-off of capital work-in-progress (CWIP) totaling ₹2.09 crore. This detail was highlighted as one factor that contributed to pressure on the consolidated bottom line. The company’s interim reporting note also referenced an exceptional item related to CWIP write-off, along with a statement that no material uncertainties were noted.

Compliance development: closure directive for Saykha Amines unit

Aarti Drugs also disclosed a regulatory development involving its Gujarat operations. The Gujarat Pollution Control Board (GPCB) issued a closure directive under Section 33A of the Water Act for the Amines unit at the Saykha facility. The directive demanded compliance actions starting July 18, 2026. This disclosure is significant because plant-level directives can affect operating continuity, timelines, and compliance-related spending, depending on the scope and duration of the required actions.

Leadership transition: chairman change and new MD from Oct 1, 2026

The board approved a leadership transition during the period of the results updates. Rashesh C. Gogri was appointed Chairman, and Chief Financial Officer Adhish P. Patil was elevated to Managing Director, effective October 1, 2026. Adhish P. Patil is set to take over as Managing Director for a five-year term starting October 1, 2026. The transition follows the planned retirement of Prakash M. Patil, the Chairman, Managing Director and CEO, effective September 30, 2026.

Key financial snapshot table (Q1 FY27)

Timeline of key events and effective dates

Market metrics and management targets cited alongside results

Market data included a quoted price of ₹390 and also a separate closing reference of ₹412.80, up ₹1.55 (0.38%). The company was also shown with market cap figures of ₹3.4K crore and ₹3,356 crore in the provided snapshots. A P/E ratio of 17.2 was cited in one snapshot, while another reference listed a trailing P/E around 19.12 to 19.34.

Separately, targets cited alongside the discussion included volume growth of 8% to 10% annually, with internal ambitions of 10% to 15%. EBITDA margins were targeted between 13.5% to 14% for FY 2027, with a note that guidance was slightly lower than an earlier 14% to 14.5% range due to geopolitical uncertainties like the West Asia war. Debt figures cited in the same context included consolidated long-term debt around ₹328 crore and short-term debt around ₹248 crore.

Why the Q1 FY27 result matters

The quarter’s central theme is the contrast between revenue momentum and profit compression. Even with stronger reported EBITDA and margin, PAT declined year-on-year, highlighting the sensitivity of net earnings to cost structures, exceptional items, and other expenses beyond core operating profit. The compliance directive at the Saykha facility adds another operational variable that investors typically monitor closely for execution and continuity. And the planned leadership transition sets a defined timetable for management change at the top, which is often an important corporate event for a mid-cap pharmaceutical manufacturer.

Conclusion

Aarti Drugs’ Q1 FY27 results showed revenue growth to around ₹703 crore while consolidated profit softened to about ₹50 crore amid cost pressures and an exceptional CWIP write-off. The company also flagged a GPCB closure directive for the Saykha Amines unit with compliance actions starting July 18, 2026. On governance, the board has set leadership changes with Prakash M. Patil retiring on September 30, 2026, and Rashesh C. Gogri and Adhish P. Patil taking charge as Chairman and Managing Director, respectively, from October 1, 2026.